ライフサイエンスコーパス: pharmacotherapy

1 more targeted and individualized approach to pharmacotherapy.

2 subcutaneous immunotherapy (SCIT), or other pharmacotherapy.

3 son's disease patients subjected to standard pharmacotherapy.

4 on complication of glioblastoma and requires pharmacotherapy.

5 ion of the viability of CBD as a psychiatric pharmacotherapy.

6 iduals whose depression has not responded to pharmacotherapy.

7 alidated predictive biomarker of response to pharmacotherapy.

8 ve disorder who do not respond to first-line pharmacotherapy.

9 here has been a paucity of novel targets for pharmacotherapy.

10 severe HDM-induced AR despite treatment with pharmacotherapy.

11 into patient-specific disease mechanism and pharmacotherapy.

12 ility for pain treatment and substance abuse pharmacotherapy.

13 lity to affective disorders, and response to pharmacotherapy.

14 receive net benefit from lifelong preventive pharmacotherapy.

15 mes but do not guide selection of CBT versus pharmacotherapy.

16 th special reference to its integration with pharmacotherapy.

17 ples early disease detection with aggressive pharmacotherapy.

18 on disease (PD) is modulated by dopaminergic pharmacotherapy.

19 about the benefits and risks of augmentation pharmacotherapy.

20 subcutaneous immunotherapy (SCIT), or other pharmacotherapy.

21 wing infarction requires a paradigm shift in pharmacotherapy.

22 nsistent with evolution in PCI technique and pharmacotherapy.

23 of oculomotor control, often is resistant to pharmacotherapy.

24 sitization suggests a synaptic target for PD pharmacotherapy.

25 es recommend treating severe depression with pharmacotherapy.

26 in the short term to intravitreal anti-VEGF pharmacotherapy.

27 patients not taking insulin as part of their pharmacotherapy.

28 to predict responses of obese individuals to pharmacotherapy.

29 nd SLIT were significantly better than other pharmacotherapy.

30 red as a possible agent in cocaine addiction pharmacotherapy.

31 ble AD may be too late for disease modifying pharmacotherapy.

32 ment of lifestyle and secondary factors, and pharmacotherapy.

33 bolic adaptation to weight loss, and obesity pharmacotherapy.

34 ations between patients treated with AIT and pharmacotherapy.

35 is a cell-mediated process without effective pharmacotherapy.

36 timuli in a manner similar to antidepressant pharmacotherapy.

37 ent modalities of surgery, radiotherapy, and pharmacotherapy.

38 d with a placebo control, as is standard for pharmacotherapy.

39 st in part, to underutilization of cessation pharmacotherapy.

40 (collectively termed youth) with OUD receive pharmacotherapy.

41 e intervention to improve early adherence to pharmacotherapy.

42 rth, and lactation, is a promising addiction pharmacotherapy.

43 subcutaneous immunotherapy (SCIT), or other pharmacotherapy.

44 selection and efficacy of smoking cessation pharmacotherapy.

45 beneficial adjunct agent in pain management pharmacotherapy.

46 esents an interesting, and novel, target for pharmacotherapy.

47 where there is a critical need for improved pharmacotherapies.

48 scape mechanisms from current antiangiogenic pharmacotherapies.

49 significantly effective compaired with other pharmacotherapies.

50 e targetable molecular mechanisms for future pharmacotherapies.

51 present a novel target for cocaine addiction pharmacotherapies.

52 he relative effectiveness of intense smoking pharmacotherapies.

53 SLIT was significantly effective than other pharmacotherapies.

54 present a novel target for cocaine addiction pharmacotherapies.

55 ibly with metabolic syndrome, lacks approved pharmacotherapies.

56 tes, and there are currently no FDA-approved pharmacotherapies.

57 ation as candidate anti-cocaine use disorder pharmacotherapies.

58 reconsider the strategies for developing ALS pharmacotherapies.

59 e the mode of action of new lipid-regulating pharmacotherapies.

60 are no Food and Drug Administration-approved pharmacotherapies.

61 y U.S. Food and Drug Administration-approved pharmacotherapies.

62 significantly effective compared with other pharmacotherapies.

63 e primary outcome-was not prevented by these pharmacotherapies.

64 thus circumventing the efficacy of standard pharmacotherapies.

65 Infants increasingly received pharmacotherapy (74% in 2004-2005 vs. 87% in 2012-2013,

66 ed to the conclusion that the combination of pharmacotherapies addressing single defects (e.g., trans

67 Likewise, the question of whether pharmacotherapies aimed at the endocannabinoid system pr

68 (650 U/day; n: 17), SCIT alone (n: 15), and pharmacotherapy alone (n: 18).

69 Both SCIT groups fared better than pharmacotherapy alone at the end of 1 year.

70 a ratio higher than that of many neurologic pharmacotherapies already in clinical use.

71 evaluating the efficacy of smoking cessation pharmacotherapies and behavioral therapies in CVD patien

72 nce for a number of established and emerging pharmacotherapies and device-based treatments for posttr

73 Despite the availability of effective pharmacotherapies and indications for some tailored phar

74 ntion and prevention strategies as it is for pharmacotherapies and pharmaceutical-oriented prevention

75 Many pharmacotherapies and psychotherapies are effective, but

76 ecially for patients given shorter half-life pharmacotherapies and who boarded in the emergency depar

77 Pharmacotherapy and bariatric surgery are promising inte

78 evidence for combined and extended cessation pharmacotherapy and behavioral strategies including prov

79 Pharmacotherapy and cardiac monitoring are effective in

80 s received recommendations for postdischarge pharmacotherapy and counseling.

81 Pharmacotherapy and device therapy are the primary metho

82 igh mortality despite advancements in modern pharmacotherapy and device therapy.

83 A thoughtful approach to both diabetes pharmacotherapy and drug management for psychotic disord

84 of hypochondriasis demonstrated benefits for pharmacotherapy and for cognitive-behavioral therapy (CB

85 Ustekinumab is a relatively new pharmacotherapy and in addition to this clinical case, w

86 multiple differences in the methods used in pharmacotherapy and psychotherapy trials, indirect compa

87 Clinical guidelines recommend combined pharmacotherapy and psychotherapy.

88 Despite advances in pharmacotherapy and stents, reinfarction after primary p

89 roduced by intensive lifestyle intervention, pharmacotherapy, and bariatric surgery.

90 et, physical activity, and behaviour change, pharmacotherapy, and bariatric surgery.

91 ine (DA) D2 antagonist haloperidol, a proven pharmacotherapy, and by HA infusion into the brain.

92 t to primary care (behavioral interventions, pharmacotherapy, and complementary or alternative therap

93 commercially insured youth with OUD received pharmacotherapy, and disparities based on sex, age, and

94 ed with the intensity of the common stepwise pharmacotherapy, and the concurrently included phenotypi

95 an enzyme that could be targeted with novel pharmacotherapy, and this may help improve dopaminergic

96 Therefore, pharmacotherapies are being sought to aid the success ra

97 se remains a public health concern for which pharmacotherapies are largely ineffective.

98 ion with inadequate response to conventional pharmacotherapy are discussed.

99 successfully with lifestyle intervention and pharmacotherapy are eligible for bariatric surgery, incl

100 reatment effect of allergy immunotherapy and pharmacotherapy are lacking.

101 py, and trials using cortical stimulation or pharmacotherapy are undergoing proof-of-principle invest

102 Despite effective pharmacotherapy, asthma continues to impair quality of l

103 care (n = 198) used more counseling and more pharmacotherapy at each follow-up assessment than those

104 to manage with no proven safe and effective pharmacotherapy available.

105 lar to that for chronic cancer-related pain, pharmacotherapy being the principal treatment modality.

106 Tobacco cessation pharmacotherapy billing codes were queried in a subgroup

107 In this randomized trial of TAVR procedural pharmacotherapy, bivalirudin did not reduce rates of maj

108 on represents a promising strategy of cancer pharmacotherapy, but resistant tumor cells often emerge.

109 ding exposure therapy, are an alternative to pharmacotherapy, but the neurobiological mechanisms are

110 us, these agents show promise as a potential pharmacotherapy by which to stem further neurodegenerati

111 is Perspective highlights the potential that pharmacotherapies capable of increasing inhibitory spina

112 py efficacy, the lack of an association with pharmacotherapy choice suggests there is scope to use NM

113 rity and has historically been used to guide pharmacotherapy choices.

114 ficient to compare efficacy within or across pharmacotherapy classes or versus behavioral therapy.

115 Pharmacotherapy, cognitive-behavioral therapy (CBT), and

116 Varenicline is the most efficacious pharmacotherapy currently available with cessation rates

117 e main objective was to determine if a novel pharmacotherapy, D-cycloserine (DCS), enhanced the effic

118 A safe and effective fetal pharmacotherapy designed to modulate gene expression ide

119 ve psychotherapy combined with best-practice pharmacotherapy does not appear to confer advantages ove

120 n one pathway or the other using traditional pharmacotherapy (e.g., systemically administered drugs).

121 vances in intracoronary imaging, and adjunct pharmacotherapy-each of which is reviewed in other paper

122 Given its impact on pharmacotherapy efficacy, the lack of an association wit

123 systematic review to examine the effects of pharmacotherapies (eg, beta blockers, hydrocortisone, an

124 tential target for development of drug abuse pharmacotherapies, especially for alcoholism, little is

125 rogressive disease course and in whom potent pharmacotherapies fail.

126 Pharmacotherapies for AD + P have limited efficacy and c

127 otherapies and indications for some tailored pharmacotherapies for African Americans (eg, heart failu

128 undamentally important in the development of pharmacotherapies for alcohol dependence.

129 s a clear need to identify and develop novel pharmacotherapies for cocaine addiction.

130 Current pharmacotherapies for depression exhibit slow onset, sid

131 tive effectiveness and long-term efficacy of pharmacotherapies for insomnia are not known.

132 Pharmacotherapies for insomnia may cause cognitive and b

133 Nonindicated and/or harmful pharmacotherapies for IPF were described as potential IP

134 derscores the urgency to develop alternative pharmacotherapies for managing pain.

135 ti-vascular endothelial growth factor (VEGF) pharmacotherapies for ME associated with CRVO, including

136 ti-vascular endothelial growth factor (VEGF) pharmacotherapies for ME, including intravitreal bevaciz

137 et effects were numerically greater than all pharmacotherapies for PAR.

138 The benefits of cannabis-based pharmacotherapies for patients concerned with increased

139 Current pharmacotherapies for symptomatic benign prostatic hyper

140 bstance use disorder (SUD), and there are no pharmacotherapies for the prevention of relapse.

141 herapeutic response and adverse effects with pharmacotherapies for tobacco dependence.

142 Combining pharmacotherapies for tobacco-dependence treatment may i

143 (mGluR5) have been implicated as a potential pharmacotherapy for a number of psychiatric diseases, in

144 No effective pharmacotherapy for acute respiratory distress syndrome

145 age of allergen immunotherapy as compared to pharmacotherapy for allergic rhinitis is the long-term e

146 a need for long-term adjunct antithrombotic pharmacotherapy for bioabsorbable EES.

147 could be one fruitful approach to innovative pharmacotherapy for bipolar disorder and related phenoty

148 d U.S. Food and Drug Administration-approved pharmacotherapy for cessation to adults who use tobacco.

149 ts of cognitive behavioral therapy (CBT) and pharmacotherapy for childhood anxiety disorders.

150 There is a need for more effective pharmacotherapy for chronic pain, including pain in inhe

151 inically available anorectic and a candidate pharmacotherapy for cocaine addiction.

152 sulfonylurea drug glibenclamide, a potential pharmacotherapy for CS.

153 randomized clinical trials comparing CBT and pharmacotherapy for depression.

154 hibitors may provide a novel and fast-acting pharmacotherapy for depression.

155 andomized clinical trials of cannabinoids as pharmacotherapy for indications other than those for whi

156 Pharmacotherapy for meningiomas has remained largely exp

157 ) procedure in rats to examine oxytocin as a pharmacotherapy for methamphetamine (meth) addiction.

158 ed, double-blind studies of oral and topical pharmacotherapy for neuropathic pain, including studies

159 Pharmacotherapy for obesity management can fill an impor

160 oncept clinical trial, predicted response to pharmacotherapy for obesity.

161 There is no effective pharmacotherapy for OSA.

162 nical settings could contribute to precision pharmacotherapy for pain and addiction.

163 ugh levodopa remains the most effective oral pharmacotherapy for Parkinson disease (PD), its use is o

164 ptifibatide (an off-label use) as procedural pharmacotherapy for patients undergoing percutaneous cor

165 The selection of pharmacotherapy for patients with allergic rhinitis (AR)

166 , mechanistically targeted, disease-specific pharmacotherapy for patients with ARDS.

167 s with mild to moderate COPD, the benefit of pharmacotherapy for reducing exacerbations was modest.

168 otic efficacy of a potential glutamate-based pharmacotherapy for schizophrenia may require the identi

169 sublingual immunotherapy (SLIT)-tablets with pharmacotherapy for seasonal allergic rhinitis (SAR) and

170 and adverse effects of single or combination pharmacotherapy for seasonal allergic rhinitis.

171 ly contribute to varenicline's efficacy as a pharmacotherapy for smoking cessation.

172 are distinct ocular advantages to anti-VEGF pharmacotherapy for some cases (such as eyes with zone I

173 nist of BCL-2, is being clinically vetted as pharmacotherapy for the treatment of acute myeloid leuke

174 tocinergic system as a target for developing pharmacotherapy for the treatment of emotional impairmen

175 rehensive assessment of GDF15 as a potential pharmacotherapy for the treatment of obesity.

176 No effective pharmacotherapy for these core deficits exists.

177 Varenicline, a pharmacotherapy for tobacco addiction, reduces alcohol c

178 eCBs in the proextinction effects of a major pharmacotherapy for trauma- and stressor-related disorde

179 s clinical trials investigating intravitreal pharmacotherapy for treatment of CRVO-associated macular

180 randomized clinical trials comparing CBT and pharmacotherapy for unipolar depression in 1,700 patient

181 omplete biochemical remission (P = 0.07) and pharmacotherapy-free interval (P = 0.06).

182 e as predictors of biochemical remission and pharmacotherapy-free interval in patients with metastati

183 alyzed as marker of biochemical response and pharmacotherapy-free interval.

184 odium homeostasis in cardiac arrhythmias and pharmacotherapy from the subcellular scale to the whole

185 th other therapies (differential g=0.06) and pharmacotherapy (g=-0.13).

186 n scores (TMS) were significantly lower than pharmacotherapy group at the end of 1 year.

187 tics (nicotine replacement therapy vs. other pharmacotherapy; group vs. one-to-one behavioural suppor

188 the risk of incidence of PTSD or ASD in the pharmacotherapy groups relative to the incidence of PTSD

189 f three 12-week open-label smoking cessation pharmacotherapy groups: (1) nicotine patch only (n = 241

190 Our results demonstrate that pharmacotherapy guided by genomic analysis, molecular mo

191 The FDA documents reported that most pharmacotherapies had risks for cognitive and behavioral

192 Few pharmacotherapies have demonstrated sufficient efficacy

193 Although psychotherapy and pharmacotherapy have proven efficacious in randomized cl

194 Current pharmacotherapies help many patients, but high rates of

195 ence was found for the efficacy of all early pharmacotherapies in the prevention of PTSD or ASD, but

196 so imply that oxytocin may be an efficacious pharmacotherapy in a wide range of psychiatric disorders

197 o 6 weeks with additional optimized standard pharmacotherapy in an uncontrolled follow-up.

198 nfer advantages over brief psychotherapy and pharmacotherapy in hastening recovery or delaying recurr

199 nd SLIT were significantly better than other pharmacotherapy in most assessment.

200 nd SLIT were significantly better than other pharmacotherapy in most assessment.

201 represents the sine qua non for antiplatelet pharmacotherapy in patients with cardiovascular diseases

202 focused treatment is an effective adjunct to pharmacotherapy in stabilizing symptoms in adult bipolar

203 quential model, which consists of the use of pharmacotherapy in the acute phase and of psychotherapy

204 ng of the risk of serious infection from IBD pharmacotherapy in the adult population.

205 apy after successful response to acute-phase pharmacotherapy in the treatment of adults with major de

206 Their pharmacotherapy included oral levodopa plus benserazide

207 inflammatory agents, and first-line systemic pharmacotherapy includes tricyclic antidepressants and a

208 assess the balance of benefits and harms of pharmacotherapy interventions for tobacco cessation in p

209 Behavioral and pharmacotherapy interventions improve rates of smoking c

210 Combined behavioral and pharmacotherapy interventions increased cessation by 82%

211 The sequential integration of CBT and pharmacotherapy is a viable strategy for preventing rela

212 In other metabolic diseases, pharmacotherapy is an accepted adjunct to lifestyle.

213 Pharmacotherapy is often severely hindered by issues rel

214 ment for borderline personality disorder and pharmacotherapy is only advised as an adjunctive treatme

215 algorithm guiding therapeutic decisions and pharmacotherapy is presented.

216 Intervening early with pharmacotherapy is recommended by major professional org

217 idence indicates that intravitreal anti-VEGF pharmacotherapy is safe and effective over 2 years for M

218 The present pharmacotherapy is sometimes ineffective and has serious

219 There is a broad consensus that opioid-based pharmacotherapy is the first-line strategy for the treat

220 Pharmacotherapy is typically inadequate unless it can be

221 Combination pharmacotherapy is utilized by 40-50% of patients to tre

222 wn to have a lower risk of side-effects than pharmacotherapy) is associated with large effect sizes.

223 of CFTR mutants and their susceptibility to pharmacotherapy, it has been recognized that mutations m

224 heral afferent sensory neurons by anticancer pharmacotherapy, leading to debilitating neuropathic pai

225 icolimbic regions, suggesting that available pharmacotherapies may alleviate deficits in the same cir

226 Pharmacotherapy may produce clinician-rated superior imp

227 transplant, in combination with the current pharmacotherapy, may be a novel strategy for hypertensio

228 with metacognitive rehabilitation (MAAT) and pharmacotherapy (MPH) can improve aspects of attention,

229 predominant role of long-form PDE4Ds in the pharmacotherapies of PDE4 inhibitors for depression and

230 (PECAM-1 or CD31) improves drug delivery and pharmacotherapy of inflammation, oxidative stress, throm

231 t BK channels are promising drug targets for pharmacotherapy of metabolic disorders and obesity.

232 athic Pain (NeuPSIG) recommendations for the pharmacotherapy of neuropathic pain based on the results

233 CSF1 and DAP12 are potential targets for the pharmacotherapy of neuropathic pain.

234 ision of the NeuPSIG recommendations for the pharmacotherapy of neuropathic pain.

235 kinetics/dynamics, and cholesterol-targeted pharmacotherapy of PAP in vitro and in vivo.

236 ility of translating pioglitazone as a novel pharmacotherapy of PAP.

237 LID), a common motor complication of current pharmacotherapy of Parkinson's disease.

238 Our findings have implications for oxytocin pharmacotherapy of social dysfunction in that whether th

239 In these patients, use of pharmacotherapy on the basis of the predominant symptom

240 In the context of contemporary pharmacotherapy, optimal antiplatelet management with pe

241 All participants received protocolized pharmacotherapy optimized by flexible dosing, psychoeduc

242 In an effort to expand the limited pharmacotherapy options for opioid use disorders, a hero

243 vent to prevent PTSD or ASD compared with no pharmacotherapy or placebo control.

244 veness of psychiatric treatments and whether pharmacotherapy or psychotherapy should be primarily use

245 or separation anxiety and who received CBT, pharmacotherapy, or the combination.

246 harmacotherapy (venlafaxine plus lithium) or pharmacotherapy plus continuation ECT.

247 Pharmacotherapies potentiating alpha7 nAChR signaling ha

248 Pharmacotherapy provision based on Nicotine Metabolite R

249 s in the field are discussed with a focus on pharmacotherapies, psychotherapies, and combined treatme

250 Seven pharmacotherapy randomized controlled trials (n=2809) an

251 lifestyle intervention may be candidates for pharmacotherapy, recommended as an adjunct.

252 In addition, careful consideration of when pharmacotherapy should be started and choice of medicati

253 y from cognitive-behavioral therapy (CBT) or pharmacotherapy, some experience divergent outcomes.

254 ors appear efficacious, but the few existing pharmacotherapy studies were short term (</=4 months), a

255 sion making is affected by abstinence and by pharmacotherapies such as nicotine replacement therapy a

256 the nature of fibroids and their diagnosis, pharmacotherapy, surgical treatment, and nonsurgical int

257 ches and molecular targets to develop future pharmacotherapy targeted to the vagus nerve for the trea

258 Thus, pharmacotherapy targeting NMDA receptors may inadvertent

259 tion (odds ratio=1.67) were more frequent in pharmacotherapy than in CBT.

260 Thus, pharmacotherapies that increase PDGF-BB secretion from p

261 arted therapies before pollen dispersal, 221 pharmacotherapy that started therapies after pollen disp

262 arted therapies before pollen dispersal, 141 pharmacotherapy that started therapies after pollen disp

263 arted therapies before pollen dispersal, 254 pharmacotherapy that started therapies after pollen disp

264 2016, of 133 SLIT with 46 SCIT, 351 primary pharmacotherapy that started therapies before pollen dis

265 ficacy of 191 SLIT with 48 SCIT, 191 primary pharmacotherapy that started therapies before pollen dis

266 third treated year with 38 SCIT, 364 primary pharmacotherapy that started therapies before pollen dis

267 balance control and is a target for obesity pharmacotherapies, the receptor-population-mediating eff

268 data on the relative benefits of "next-step" pharmacotherapies to improve outcomes for individuals wi

269 The ability of pharmacotherapies to prevent relapse and maintain effica

270 g such mechanisms will inform development of pharmacotherapies to reduce carcinogenesis.

271 as a potential target for the development of pharmacotherapies to treat alcohol use disorders, yet li

272 Varenicline is an effective pharmacotherapy to aid smoking cessation.

273 rescription drug coverage for evidence-based pharmacotherapy to commercially insured post-myocardial

274 nalysis, we sought to identify predictors of pharmacotherapy to further the clinical implementation o

275 Treatment options are broad ranging, from pharmacotherapy to invasive neuromodulation and experime

276 Such techniques may allow tailoring of pharmacotherapy to potentiate thrombus instability, thro

277 Pharmacotherapy to rapidly relieve suicidal ideation in

278 mation for a more individualized approach to pharmacotherapy, to maximize the benefit versus risk rat

279 macological effects and aid a more efficient pharmacotherapy towards neuropsychological conditions.

280 allowed rescue medication use, whereas most pharmacotherapy trials did not.

281 Reasons for treatment discontinuation in pharmacotherapy trials were infrequently reported (35%),

282 In adjusted analysis, pharmacotherapy type was not associated with NMR status,

283 Weight loss after pharmacotherapy varies greatly.

284 d remitted were randomly assigned to receive pharmacotherapy (venlafaxine plus lithium) or pharmacoth

285 Pharmacotherapy was more effective in preventing PTSD or

286 ial, the use of allergic rhinoconjunctivitis pharmacotherapy was significantly less (27% relative dif

287 Management type (observation alone vs pharmacotherapy) was determined via medical record revie

288 Risks associated with aspects of pharmacotherapy were also examined in the full cohort.

289 Fifty children with asthma and receiving pharmacotherapy were randomized into three groups as: su

290 , and use of antiviral and immunosuppressive pharmacotherapy, were evaluated.

291 Therefore, effective combination pharmacotherapies, which have included non-steroidal ant

292 red as a potential moderator of efficacy for pharmacotherapies with neuroimmune effects, such as IBUD

293 level I evidence suggests that intravitreal pharmacotherapy with anti-VEGF agents is effective and s

294 oral and psychological symptoms of dementia, pharmacotherapy with antidementia drugs, and use of pote

295 Targeted pharmacotherapy with Avpr1b agonists or deep brain stimu

296 n components of existing care models include pharmacotherapy with buprenorphine or naltrexone, provid

297 subjects then received 8 wk of standardized pharmacotherapy with escitalopram.

298 Pharmacotherapy with methylphenidate (MPH) seems to be t

299 to assess whether adjunctive anti-ischaemic pharmacotherapy with ranolazine would improve the progno

300 l to evaluate the efficacy of antidepressant pharmacotherapy, with and without complicated grief psyc